MICHAEL REED FRANCIS, D.O.
Osteopathic Medicine at 500, Logan, UT

7531555, May 12, 2009

Sep 30, 2004

10/956957

Roger L. Papke - Gainesville FL, US
Nicole A. Horenstein - Gainesville FL, US
Michael M. Francis - Salt Lake City UT, US
Kyung Il Choi - Seoul, KR

University of Florida Research Foundation, Inc. - Gainesville FL

A61K 31/445, C07D 211/40

514327, 546242

The present invention concerns methods for treating or preventing neurological disorders characterized by dysfunction of nicotinic acetylcholine receptors by administering 2,2,6,6-tetramethylpiperidin-4-yl heptanoate (TMPH), or a pharmaceutically acceptable salt thereof, to the patient. In another aspect, the present invention pertains to pharmaceutical compositions containing TMPH, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. In another aspect, the present invention pertains to methods for selectively inhibiting nicotinic acetylcholine receptors that lack an α5, α6, or β3 subunit by contacting an effective amount of TMPH, or a pharmaceutically acceptable salt thereof, to the receptor. The method for selectively inhibiting nicotinic acethylcholine receptors that lack an α5 subunit can be carried out in vivo or in vitro.

2012032, Dec 27, 2012

Jun 18, 2012

13/526076

ROGER L. PAPKE - Gainesville FL, US
Nicole A. Horenstein - Gainesville FL, US
Michael M. Francis - Salt Lake City UT, US
Kyung Il Choi - Seoul, KR

UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. - Gainesville FL

A61K 31/4465, A61K 31/4515, A61K 31/454, A61P 25/14, A61K 31/55, A61P 25/34, A61P 25/00, C07D 211/46, C12N 5/071

514217, 546242, 514315, 514327, 514322, 435375

The present invention concerns methods for treating or preventing neurological disorders characterized by dysfunction of nicotinic acetylcholine receptors by administering 2,2,6,6-tetramethylpiperidin-4-yl heptanoate (TMPH), or a pharmaceutically acceptable salt thereof, to the patient. In another aspect, the present invention pertains to pharmaceutical compositions containing TMPH, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. In another aspect, the present invention pertains to methods for selectively inhibiting nicotinic acetylcholine receptors that lack an α5, α6, or β3 subunit by contacting an effective amount of TMPH, or a pharmaceutically acceptable salt thereof, to the receptor. The method for selectively inhibiting nicotinic acethylcholine receptors that lack an α5 subunit can be carried out in vivo or in vitro.

2009006, Mar 5, 2009

Nov 4, 2008

12/264768

Roger L. Papke - Gainesville FL, US
Nicole A. Horenstein - Gainesville FL, US
Michael M. Francis - Salt Lake City UT, US
Kyung Il Choi - Seoul, KR

A61K 31/4465, C07D 211/44, C07K 14/705

514315, 546242, 530409

The present invention concerns methods for treating or preventing neurological disorders characterized by dysfunction of nicotinic acetylcholine receptors by administering 2,2,6,6-tetramethylpiperidin-4-yl heptanoate (TMPH), or a pharmaceutically acceptable salt thereof, to the patient. In another aspect, the present invention pertains to pharmaceutical compositions containing TMPH, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. In another aspect, the present invention pertains to methods for selectively inhibiting nicotinic acetylcholine receptors that lack an α5, α6, or β3 subunit by contacting an effective amount of TMPH, or a pharmaceutically acceptable salt thereof, to the receptor. The method for selectively inhibiting nicotinic acethylcholine receptors that lack an α5 subunit can be carried out in vivo or in vitro.